VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: May 31, 2023

VALNEVA - Declaration of shares and voting rights: May 31, 2023

VALNEVA

Declaration of shares and voting rights

May 31, 2023

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: June 7, 2023

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



138,896,600



ordinary shares with a par value of €0.15 each
161,012,263 



Double voting rights granted on 7,355 ordinary shares



 



Conversion of 549,632 free ordinary shares into ordinary shares



 



Transfer of 10 shares with double voting rights into bearer form



 



Sale of 500,000 shares with double voting rights



 
Between May 3 & May 31, 2023



 



May 10, 2023



 



May 12, 2023



 



Between May 25 & May 30, 2023



 
160,887,941

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
07/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provid...

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the yearChief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership Lyon (France), February 19, 2026 – (Nasdaq: VALN; Euronext Paris...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch